Skip to main content
NCBI home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1990 Jan;3(1):66–98. doi: 10.1128/cmr.3.1.66

Toxigenic clostridia.

C L Hatheway 1
PMCID: PMC358141  PMID: 2404569

Abstract

Toxigenic clostridia belonging to 13 recognized species are discussed in this review. Each species or group of organisms is, in general, introduced by presenting the historical aspects of its discovery by early investigators of human and animal diseases. The diseases caused by each species or group are described and usually discussed in relation to the toxins involved in the pathology. Morphological and physiological characteristics of the organisms are described. Finally, the toxins produced by each organism are listed, with a presentation of their biological activities and physical and biochemical characteristics. The complete amino acid sequences for some are known, and some of the genes have been cloned. The term toxin is used loosely to include the various antigenic protein products of these organisms with biological and serological activities which have served as distinguishing characteristics for differentiation and classification. Some of these factors are not truly toxic and have no known role in pathogenicity. Some of the interesting factors common to more than one species or group are the following: neurotoxins, lethal toxins, lecithinases, oxygen-labile hemolysins, binary toxins, and ADP-ribosyltransferases. Problems in bacterial nomenclature and designation of biologically active factors are noted.

Full text

PDF
66

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AIKAT B. K., DIBLE J. H. The local and general effects of cultures and culture-filtrates of Clostridium oedematiens, CL. septicum, CL. sporogenes and CL. histolyticum. J Pathol Bacteriol. 1960 Apr;79:227–241. doi: 10.1002/path.1700790203. [DOI] [PubMed] [Google Scholar]
  2. Aktories K., Bärmann M., Ohishi I., Tsuyama S., Jakobs K. H., Habermann E. Botulinum C2 toxin ADP-ribosylates actin. Nature. 1986 Jul 24;322(6077):390–392. doi: 10.1038/322390a0. [DOI] [PubMed] [Google Scholar]
  3. Aktories K., Weller U., Chhatwal G. S. Clostridium botulinum type C produces a novel ADP-ribosyltransferase distinct from botulinum C2 toxin. FEBS Lett. 1987 Feb 9;212(1):109–113. doi: 10.1016/0014-5793(87)81566-1. [DOI] [PubMed] [Google Scholar]
  4. Alouf J. E., Jolivet-Reynaud C. Purification and characterization of Clostridium perfringens delta-toxin. Infect Immun. 1981 Feb;31(2):536–546. doi: 10.1128/iai.31.2.536-546.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Alpern R. J., Dowell V. R., Jr Clostridium septicum infections and malignancy. JAMA. 1969 Jul 21;209(3):385–388. [PubMed] [Google Scholar]
  6. Altwegg M., Hatheway C. L. Multilocus enzyme electrophoresis of Clostridium argentinense (Clostridium botulinum toxin type G) and phenotypically similar asaccharolytic clostridia. J Clin Microbiol. 1988 Nov;26(11):2447–2449. doi: 10.1128/jcm.26.11.2447-2449.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Arbuthnott J. P. Role of exotoxins in bacterial pathogenicity. J Appl Bacteriol. 1978 Jun;44(3):329–345. doi: 10.1111/j.1365-2672.1978.tb00808.x. [DOI] [PubMed] [Google Scholar]
  8. Arnon S. S. Infant botulism: anticipating the second decade. J Infect Dis. 1986 Aug;154(2):201–206. doi: 10.1093/infdis/154.2.201. [DOI] [PubMed] [Google Scholar]
  9. Arnon S. S., Midura T. F., Damus K., Thompson B., Wood R. M., Chin J. Honey and other environmental risk factors for infant botulism. J Pediatr. 1979 Feb;94(2):331–336. doi: 10.1016/s0022-3476(79)80863-x. [DOI] [PubMed] [Google Scholar]
  10. Arnon S. S., Midura T. F., Damus K., Wood R. M., Chin J. Intestinal infection and toxin production by Clostridium botulinum as one cause of sudden infant death syndrome. Lancet. 1978 Jun 17;1(8077):1273–1277. doi: 10.1016/s0140-6736(78)91264-3. [DOI] [PubMed] [Google Scholar]
  11. BATTY I., WALKER P. D. Differentiation of Clostridium septicum and Clostridium chauvoei by the use of fluorescent labelled antibodies. J Pathol Bacteriol. 1963 Apr;85:517–521. doi: 10.1002/path.1700850232. [DOI] [PubMed] [Google Scholar]
  12. BLADEN H. A., NYLEN M. U., FITZGERALD R. J. INTERNAL STRUCTURES OF A EUBACTERIUM SP. DEMONSTRATED BY THE NEGATIVE STAINING TECHNIQUE. J Bacteriol. 1964 Sep;88:763–770. doi: 10.1128/jb.88.3.763-770.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. BOWEN H. E. A comparison of the lethal and hemolytic toxins of Clostridium histolyticum. Yale J Biol Med. 1952 Nov;25(2):131–138. [PMC free article] [PubMed] [Google Scholar]
  14. Banga H. S., Gupta S. K., Feinstein M. B. Botulinum toxin D ADP-ribosylates a 22-24 KDa membrane protein in platelets and HL-60 cells that is distinct from p21N-ras. Biochem Biophys Res Commun. 1988 Aug 30;155(1):263–269. doi: 10.1016/s0006-291x(88)81078-7. [DOI] [PubMed] [Google Scholar]
  15. Bartlett J. G., Moon N., Chang T. W., Taylor N., Onderdonk A. B. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978 Nov;75(5):778–782. [PubMed] [Google Scholar]
  16. Baskerville M., Wood M., Seamer J. H. Clostridium perfringens type E enterotoxaemia in rabbits. Vet Rec. 1980 Jul 5;107(1):18–19. doi: 10.1136/vr.107.1.18. [DOI] [PubMed] [Google Scholar]
  17. Beland S., Rossier E. Isolement et identification de Clostridium tetani dans le sol des Cantons de l'Est de la province de Québec. Can J Microbiol. 1973 Dec;19(12):1513–1518. [PubMed] [Google Scholar]
  18. Berger S. A., Cherubin C. E., Nelson S., Levine L. Tetanus despite preexisting antitetanus antibody. JAMA. 1978 Aug 25;240(8):769–770. [PubMed] [Google Scholar]
  19. Bernheimer A. W. PARALLELISM IN THE LETHAL AND HEMOLYTIC ACTIVITY OF THE TOXIN OF CLOSTRIDIUM SEPTICUM. J Exp Med. 1944 Oct 1;80(4):309–320. doi: 10.1084/jem.80.4.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Berry P. R., Rodhouse J. C., Hughes S., Bartholomew B. A., Gilbert R. J. Evaluation of ELISA, RPLA, and Vero cell assays for detecting Clostridium perfringens enterotoxin in faecal specimens. J Clin Pathol. 1988 Apr;41(4):458–461. doi: 10.1136/jcp.41.4.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Bhown A. S., Habeerb A. F. Structural studies on epsilon-prototoxin of Clostridium perfringens type D. Localization of the site of tryptic scission necessary for activation to epsilon-toxin. Biochem Biophys Res Commun. 1977 Oct 10;78(3):889–896. doi: 10.1016/0006-291x(77)90506-x. [DOI] [PubMed] [Google Scholar]
  22. Bigalke H., Müller H., Dreyer F. Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure. Toxicon. 1986;24(11-12):1065–1074. doi: 10.1016/0041-0101(86)90133-9. [DOI] [PubMed] [Google Scholar]
  23. Bizzini B. Tetanus toxin. Microbiol Rev. 1979 Jun;43(2):224–240. doi: 10.1128/mr.43.2.224-240.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Bleck T. P. Pharmacology of tetanus. Clin Neuropharmacol. 1986;9(2):103–120. doi: 10.1097/00002826-198604000-00001. [DOI] [PubMed] [Google Scholar]
  25. Bond M. D., Van Wart H. E. Characterization of the individual collagenases from Clostridium histolyticum. Biochemistry. 1984 Jun 19;23(13):3085–3091. doi: 10.1021/bi00308a036. [DOI] [PubMed] [Google Scholar]
  26. Bond M. D., Van Wart H. E. Purification and separation of individual collagenases of Clostridium histolyticum using red dye ligand chromatography. Biochemistry. 1984 Jun 19;23(13):3077–3085. doi: 10.1021/bi00308a035. [DOI] [PubMed] [Google Scholar]
  27. Bond M. D., Van Wart H. E. Relationship between the individual collagenases of Clostridium histolyticum: evidence for evolution by gene duplication. Biochemistry. 1984 Jun 19;23(13):3092–3099. doi: 10.1021/bi00308a037. [DOI] [PubMed] [Google Scholar]
  28. Borriello S. P., Carman R. J. Association of iota-like toxin and Clostridium spiroforme with both spontaneous and antibiotic-associated diarrhea and colitis in rabbits. J Clin Microbiol. 1983 Mar;17(3):414–418. doi: 10.1128/jcm.17.3.414-418.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Borriello S. P., Larson H. E., Welch A. R., Barclay F., Stringer M. F., Bartholomew B. A. Enterotoxigenic Clostridium perfringens: a possible cause of antibiotic-associated diarrhoea. Lancet. 1984 Feb 11;1(8372):305–307. doi: 10.1016/s0140-6736(84)90359-3. [DOI] [PubMed] [Google Scholar]
  30. Brin M. F., Fahn S., Moskowitz C., Friedman A., Shale H. M., Greene P. E., Blitzer A., List T., Lange D., Lovelace R. E. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2(4):237–254. doi: 10.1002/mds.870020402. [DOI] [PubMed] [Google Scholar]
  31. Browdie D. A., Davis J. H., Koplewitz M. J., Corday L., Leadbetter A. W. Clostridium sordelli infection. J Trauma. 1975 Jun;15(6):515–518. doi: 10.1097/00005373-197506000-00011. [DOI] [PubMed] [Google Scholar]
  32. Burke G. S. Notes on Bacillus botulinus. J Bacteriol. 1919 Sep;4(5):555–570.1. doi: 10.1128/jb.4.5.555-570.1.1919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Buxton D. Further studies on the mode of action of Clostridium welchii type-D epsilon toxin. J Med Microbiol. 1978 Aug;11(3):293–298. doi: 10.1099/00222615-11-3-293. [DOI] [PubMed] [Google Scholar]
  34. CRAIG J. P., MILES A. A. Some properties of the iota-toxin of Clostridium welchii, including its action on capillary permeability. J Pathol Bacteriol. 1961 Apr;81:481–493. doi: 10.1002/path.1700810221. [DOI] [PubMed] [Google Scholar]
  35. Carman R. J., Borriello S. P. Clostridium spiroforme isolated from rabbits with diarrhoea. Vet Rec. 1982 Nov 13;111(20):461–462. doi: 10.1136/vr.111.20.461. [DOI] [PubMed] [Google Scholar]
  36. Carman R. J., Borriello S. P. Infectious nature of Clostridium spiroforme-mediated rabbit enterotoxaemia. Vet Microbiol. 1984 Sep;9(5):497–502. doi: 10.1016/0378-1135(84)90070-1. [DOI] [PubMed] [Google Scholar]
  37. Cato E. P., Hash D. E., Holdeman L. V., Moore W. E. Electrophoretic study of Clostridium species. J Clin Microbiol. 1982 Apr;15(4):688–702. doi: 10.1128/jcm.15.4.688-702.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Cavanagh P., McPherson K. The thiacetazone sensitivity of Mycobacterium tuberculosis. J Med Microbiol. 1969 Aug;2(3):237–242. doi: 10.1099/00222615-2-3-237. [DOI] [PubMed] [Google Scholar]
  39. Chia J. K., Clark J. B., Ryan C. A., Pollack M. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med. 1986 Jul 24;315(4):239–241. doi: 10.1056/NEJM198607243150407. [DOI] [PubMed] [Google Scholar]
  40. Claus K. D., Kolbe D. R. Immunogenicity of Clostridium septicum in guinea pigs. Am J Vet Res. 1979 Dec;40(12):1752–1756. [PubMed] [Google Scholar]
  41. Cowell J. L., Grushoff-Kosyk P. S., Bernheimer A. W. Purification of cereolysin and the electrophoretic separation of the active (reduced) and inactive (oxidized) forms of the purified toxin. Infect Immun. 1976 Jul;14(1):144–154. doi: 10.1128/iai.14.1.144-154.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. DAVIS J. B., MATTMAN L. H., WILEY M. Clostridium botulinum in a fatal wound infection. J Am Med Assoc. 1951 Jun 16;146(7):646–648. doi: 10.1001/jama.1951.63670070006009d. [DOI] [PubMed] [Google Scholar]
  43. DISCHE F. E., ELEK S. D. Experimental food-poisoning by Clostridium welchii. Lancet. 1957 Jul 13;273(6985):71–74. doi: 10.1016/s0140-6736(57)92545-x. [DOI] [PubMed] [Google Scholar]
  44. Darakhshan H., Lauerman L. H. Some properties of beta toxin produced by Clostridium haemolyticum strain IRP-135. Comp Immunol Microbiol Infect Dis. 1981;4(3-4):307–316. doi: 10.1016/0147-9571(81)90017-5. [DOI] [PubMed] [Google Scholar]
  45. DasGupta B. E., Rasmussen S. Amino acid composition of Clostridium botulinum type F neurotoxin. Toxicon. 1983;21(4):566–569. doi: 10.1016/0041-0101(83)90136-8. [DOI] [PubMed] [Google Scholar]
  46. DasGupta B. R., Rasmussen S. Purification and amino acid composition of type E botulinum neurotoxin. Toxicon. 1983;21(4):535–545. doi: 10.1016/0041-0101(83)90131-9. [DOI] [PubMed] [Google Scholar]
  47. DasGupta B. R., Sathyamoorthy V. Purification and amino acid composition of type A botulinum neurotoxin. Toxicon. 1984;22(3):415–424. doi: 10.1016/0041-0101(84)90085-0. [DOI] [PubMed] [Google Scholar]
  48. DasGupta B. R., Woody M. A. Amino acid composition of Clostridium botulinum type B neurotoxin. Toxicon. 1984;22(2):312–315. doi: 10.1016/0041-0101(84)90033-3. [DOI] [PubMed] [Google Scholar]
  49. Dasgupta B. R., Datta A. Botulinum neurotoxin type B (strain 657): partial sequence and similarity with tetanus toxin. Biochimie. 1988 Jun;70(6):811–817. doi: 10.1016/0300-9084(88)90111-3. [DOI] [PubMed] [Google Scholar]
  50. Decker K., Jungermann K., Thauer R. K. Energy production in anaerobic organisms. Angew Chem Int Ed Engl. 1970 Feb;9(2):138–158. doi: 10.1002/anie.197001381. [DOI] [PubMed] [Google Scholar]
  51. Dezfulian M., Hatheway C. L., Yolken R. H., Bartlett J. G. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum type A and type B toxins in stool samples of infants with botulism. J Clin Microbiol. 1984 Sep;20(3):379–383. doi: 10.1128/jcm.20.3.379-383.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Dolman C. E., Chang E. Bacteriophages of Clostridium botulinum. Can J Microbiol. 1972 Jan;18(1):67–76. doi: 10.1139/m72-011. [DOI] [PubMed] [Google Scholar]
  53. Dowell V. R., Jr, McCroskey L. M., Hatheway C. L., Lombard G. L., Hughes J. M., Merson M. H. Coproexamination for botulinal toxin and clostridium botulinum. A new procedure for laboratory diagnosis of botulism. JAMA. 1977 Oct 24;238(17):1829–1832. [PubMed] [Google Scholar]
  54. Duncan C. L., Strong D. H. Ileal loop fluid accumulation and production of diarrhea in rabbits by cell-free products of Clostridium perfringens. J Bacteriol. 1969 Oct;100(1):86–94. doi: 10.1128/jb.100.1.86-94.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Duncan C. L., Strong D. H., Sebald M. Sporulation and enterotoxin production by mutants of Clostridium perfringens. J Bacteriol. 1972 Apr;110(1):378–391. doi: 10.1128/jb.110.1.378-391.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Eisel U., Jarausch W., Goretzki K., Henschen A., Engels J., Weller U., Hudel M., Habermann E., Niemann H. Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. EMBO J. 1986 Oct;5(10):2495–2502. doi: 10.1002/j.1460-2075.1986.tb04527.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Eklund M. W., Poysky F. T. Activation of a toxic component of Clostridium botulinum types C and D by trypsin. Appl Microbiol. 1972 Jul;24(1):108–113. doi: 10.1128/am.24.1.108-113.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Eklund M. W., Poysky F. T., Boatman E. S. Bacteriophages of Clostridium botulinum types A, B, E, and F and nontoxigenic strains resembling type E. J Virol. 1969 Feb;3(2):270–274. doi: 10.1128/jvi.3.2.270-274.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Eklund M. W., Poysky F. T. Interconversion of type C and D strains of Clostridium botulinum by specific bacteriophages. Appl Microbiol. 1974 Jan;27(1):251–258. doi: 10.1128/am.27.1.251-258.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Eklund M. W., Poysky F. T., Meyers J. A., Pelroy G. A. Interspecies conversion of Clostridium botulinum type C to Clostridium novyi type A by bacteriophage. Science. 1974 Nov 1;186(4162):456–458. doi: 10.1126/science.186.4162.456. [DOI] [PubMed] [Google Scholar]
  61. Eklund M. W., Poysky F. T., Mseitif L. M., Strom M. S. Evidence for plasmid-mediated toxin and bacteriocin production in Clostridium botulinum type G. Appl Environ Microbiol. 1988 Jun;54(6):1405–1408. doi: 10.1128/aem.54.6.1405-1408.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Eklund M. W., Poysky F. T., Peterson M. E., Meyers J. A. Relationship of bacteriophages to alpha toxin production in Clostridium novyi types A and B. Infect Immun. 1976 Sep;14(3):793–803. doi: 10.1128/iai.14.3.793-803.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Fairweather N. F., Lyness V. A. The complete nucleotide sequence of tetanus toxin. Nucleic Acids Res. 1986 Oct 10;14(19):7809–7812. doi: 10.1093/nar/14.19.7809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Finn C. W., Jr, Silver R. P., Habig W. H., Hardegree M. C., Zon G., Garon C. F. The structural gene for tetanus neurotoxin is on a plasmid. Science. 1984 May 25;224(4651):881–884. doi: 10.1126/science.6326263. [DOI] [PubMed] [Google Scholar]
  65. Fitzgerald R. J., McBride J. A., Jordon H. V. Helically coiled micro-organism from caecum contents of the rat. Nature. 1965 Mar 13;205(976):1133–1134. doi: 10.1038/2051133a0. [DOI] [PubMed] [Google Scholar]
  66. Gadalla M. S., Collee J. G. The relationship of the neuraminidase of Clostridium septicum to the haemagglutinin and other soluble products of the organism. J Pathol Bacteriol. 1968 Jul;96(1):169–184. doi: 10.1002/path.1700960118. [DOI] [PubMed] [Google Scholar]
  67. Gansel M., Penner R., Dreyer F. Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor nerve terminals. Pflugers Arch. 1987 Aug;409(4-5):533–539. doi: 10.1007/BF00583812. [DOI] [PubMed] [Google Scholar]
  68. Gautier E., Gallusser A., Despland P. A. Botulisme infantile. Helv Paediatr Acta. 1989 Jun;43(5-6):521–530. [PubMed] [Google Scholar]
  69. George W. L., Sutter V. L., Citron D., Finegold S. M. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol. 1979 Feb;9(2):214–219. doi: 10.1128/jcm.9.2.214-219.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Giménez D. F., Ciccarelli A. S. Studies on strain 84 of Clostridium botulinum. Zentralbl Bakteriol Orig. 1970;215(2):212–220. [PubMed] [Google Scholar]
  71. Giménez J. A., Sugiyama H. Comparison of toxins of Clostridium butyricum and Clostridium botulinum type E. Infect Immun. 1988 Apr;56(4):926–929. doi: 10.1128/iai.56.4.926-929.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Goldner S. B., Solberg M., Jones S., Post L. S. Enterotoxin synthesis by nonsporulating cultures of Clostridium perfringens. Appl Environ Microbiol. 1986 Sep;52(3):407–412. doi: 10.1128/aem.52.3.407-412.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Granum P. E., Whitaker J. R., Skjelkvåle R. Trypsin activation of enterotoxin from Clostridium perfringens type A: fragmentation and some physicochemical properties. Biochim Biophys Acta. 1981 May 29;668(3):325–332. doi: 10.1016/0005-2795(81)90165-3. [DOI] [PubMed] [Google Scholar]
  74. Gurwith M. J., Langston C., Citron D. M. Toxin-producing bacteria in infants. Lack of an association with sudden infant death syndrome. Am J Dis Child. 1981 Dec;135(12):1104–1106. doi: 10.1001/archpedi.1981.02130360012006. [DOI] [PubMed] [Google Scholar]
  75. HOBBS B. C., SMITH M. E., OAKLEY C. L., WARRACK G. H., CRUICKSHANK J. C. Clostridium welchii food poisoning. J Hyg (Lond) 1953 Mar;51(1):75–101. doi: 10.1017/s0022172400015515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Habeeb A. F. Studies on epsilon-prototoxin of Clostridium perfringens type D. I. Purification methods: evidence for multiple forms of epsilon-prototoxin. Arch Biochem Biophys. 1969 Mar;130(1):430–440. doi: 10.1016/0003-9861(69)90055-1. [DOI] [PubMed] [Google Scholar]
  77. Habeeb A. F. Studies on epsilon-prototoxin of Clostridium perfringens type D. Physicochemical and chemical properties of epsilon-prototoxin. Biochim Biophys Acta. 1975 Nov 18;412(1):62–69. doi: 10.1016/0005-2795(75)90339-6. [DOI] [PubMed] [Google Scholar]
  78. Habermann E., Dreyer F. Clostridial neurotoxins: handling and action at the cellular and molecular level. Curr Top Microbiol Immunol. 1986;129:93–179. doi: 10.1007/978-3-642-71399-6_2. [DOI] [PubMed] [Google Scholar]
  79. Hall J. D., McCroskey L. M., Pincomb B. J., Hatheway C. L. Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol. 1985 Apr;21(4):654–655. doi: 10.1128/jcm.21.4.654-655.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Hara T., Matsuda M., Yoneda M. Isolation and some properties of nontoxigenic derivatives of a strain of Clostridium tetani. Biken J. 1977 Dec;20(3-4):105–115. [PubMed] [Google Scholar]
  81. Hardegree M. C., Palmer A. E., Duffin N. Tetanolysin: in-vivo effects in animals. J Infect Dis. 1971 Jan;123(1):51–60. doi: 10.1093/infdis/123.1.51. [DOI] [PubMed] [Google Scholar]
  82. Hatheway C. L., McCroskey L. M. Examination of feces and serum for diagnosis of infant botulism in 336 patients. J Clin Microbiol. 1987 Dec;25(12):2334–2338. doi: 10.1128/jcm.25.12.2334-2338.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Hauschild A. H. Criteria and procedures for implicating Clostridium perfringens in food-borne outbreaks. Can J Public Health. 1975 Sep-Oct;66(5):388–392. [PubMed] [Google Scholar]
  84. Hauschild A. H., Hilsheimer R. Purification and characteristics of the enterotoxin of Clostridium perfringens type A. Can J Microbiol. 1971 Nov;17(11):1425–1433. doi: 10.1139/m71-227. [DOI] [PubMed] [Google Scholar]
  85. Heinzel G., Lenk V., Schneider V. Ergebnisse bakteriologischer Untersuchungen zum plötzlichen unerwarteten Säuglingstod unter besonderer Berücksichtigung des Säuglingsbotulismus. Beitr Gerichtl Med. 1985;43:378–380. [PubMed] [Google Scholar]
  86. Helting T. B., Zwisler O. Structure of tetanus toxin. I. Breakdown of the toxin molecule and discrimination between polypeptide fragments. J Biol Chem. 1977 Jan 10;252(1):187–193. [PubMed] [Google Scholar]
  87. Hewitt J., Morris J. G. Superoxide dismutase in some obligately anaerobic bacteria. FEBS Lett. 1975 Feb 15;50(3):315–318. doi: 10.1016/0014-5793(75)80518-7. [DOI] [PubMed] [Google Scholar]
  88. Hoch D. H., Romero-Mira M., Ehrlich B. E., Finkelstein A., DasGupta B. R., Simpson L. L. Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1692–1696. doi: 10.1073/pnas.82.6.1692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Hoffman R. E., Pincomb B. J., Skeels M. R. Type F infant botulism. Am J Dis Child. 1982 Mar;136(3):270–271. doi: 10.1001/archpedi.1982.03970390084021. [DOI] [PubMed] [Google Scholar]
  90. Hogan S. F., Ireland K. Fatal acute spontaneous endometritis resulting from Clostridium sordelli. Am J Clin Pathol. 1989 Jan;91(1):104–106. doi: 10.1093/ajcp/91.1.104. [DOI] [PubMed] [Google Scholar]
  91. Holmes H. T., Sonn R. J., Patton N. M. Isolation of Clostridium spiroforme from rabbits. Lab Anim Sci. 1988 Apr;38(2):167–168. [PubMed] [Google Scholar]
  92. Howard F. M., Flynn D. M., Bradley J. M., Noone P., Szawatkowski M. Outbreak of necrotising enterocolitis caused by Clostridium butyricum. Lancet. 1977 Nov 26;2(8048):1099–1102. doi: 10.1016/s0140-6736(77)90546-3. [DOI] [PubMed] [Google Scholar]
  93. Inoue K., Iida H. Bacteriophages of Clostridium botulinum. J Virol. 1968 May;2(5):537–540. doi: 10.1128/jvi.2.5.537-540.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Iwanejko L. A., Routledge M. N., Stewart G. S. Cloning in Escherichia coli of the enterotoxin gene from Clostridium perfringens type A. J Gen Microbiol. 1989 Apr;135(4):903–909. doi: 10.1099/00221287-135-4-903. [DOI] [PubMed] [Google Scholar]
  95. Iwasaki M., Ohishi I., Sakaguchi G. Evidence that botulinum C2 toxin has two dissimilar components. Infect Immun. 1980 Aug;29(2):390–394. doi: 10.1128/iai.29.2.390-394.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Izumi N., Kondo H., Ohishi I., Sakaguchi G. Purification and characterization of alpha-toxin of Clostridium oedematiens type A. Jpn J Med Sci Biol. 1983 Jun;36(3):135–146. [PubMed] [Google Scholar]
  97. Izumi N., Niiro M., Kondo H. Clostridium oedematiens type A toxin: the correlation between the lethal and edematizing activities. Jpn J Med Sci Biol. 1983 Apr;36(2):67–74. doi: 10.7883/yoken1952.36.67. [DOI] [PubMed] [Google Scholar]
  98. Jansen B. C. The quantitative determination of the toxic factors produced by Clostridium botulinum (Van Ermengem, 1896) types C and D. Onderstepoort J Vet Res. 1971 Sep;38(3):177–179. [PubMed] [Google Scholar]
  99. Jansen B. C. The toxic antigenic factors produced by Clostridium botulinum types C and D. Onderstepoort J Vet Res. 1971 Jun;38(2):93–98. [PubMed] [Google Scholar]
  100. Jensen W. I., Duncan R. M. The susceptibility of the mallard duck (Anas platyrhynchos) to Clostridium botulinum C2 toxin. Jpn J Med Sci Biol. 1980 Apr;33(2):81–86. doi: 10.7883/yoken1952.33.81. [DOI] [PubMed] [Google Scholar]
  101. Jolivet-Reynaud C., Moreau H., Alouf J. E. Purification of alpha toxin from Clostridium perfringens: phospholipase C. Methods Enzymol. 1988;165:91–94. doi: 10.1016/s0076-6879(88)65017-8. [DOI] [PubMed] [Google Scholar]
  102. Kameyama S., Akama K. Purification and some properties of kappa toxin of Clostridium perfringens. Jpn J Med Sci Biol. 1971 Feb;24(1):9–23. doi: 10.7883/yoken1952.24.9. [DOI] [PubMed] [Google Scholar]
  103. Kameyama S., Sato H., Murata R. The role of alpha-toxin of Clostridium perfringens in experimental gas gangrene in guinea pigs. Jpn J Med Sci Biol. 1972 Jun;25(3):200–200. [PubMed] [Google Scholar]
  104. King A., Rampling A., Wight D. G., Warren R. E. Neutropenic enterocolitis due to Clostridium septicum infection. J Clin Pathol. 1984 Mar;37(3):335–343. doi: 10.1136/jcp.37.3.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Kobel T., Marti M. C. 100 ans après. Découverte du bacille du tétanos (1884). Rev Med Suisse Romande. 1985 Jun;105(6):547–556. [PubMed] [Google Scholar]
  106. Koopman J. P., Kennis H. M. Differentiation of bacteria isolated from mouse ceca. Z Versuchstierkd. 1977;19(3):174–181. [PubMed] [Google Scholar]
  107. Kozaki S., Miyazaki S., Sakaguchi G. Structure of Clostridium botulinum type B derivative toxin: inhibition with a fragment of toxin from binding to synaptosomal fraction [proceedings]. Jpn J Med Sci Biol. 1978 Apr;31(2):163–166. [PubMed] [Google Scholar]
  108. LAYTON W. M., Jr, HALLESY D. W. DEFORMITY OF FORELIMB IN RATS: ASSOCIATION WITH HIGH DOSES OF ACETAZOLAMIDE. Science. 1965 Jul 16;149(3681):306–308. doi: 10.1126/science.149.3681.306-a. [DOI] [PubMed] [Google Scholar]
  109. Laird W. J., Aaronson W., Silver R. P., Habig W. H., Hardegree M. C. Plasmid-associated toxigenicity in Clostridium tetani. J Infect Dis. 1980 Oct;142(4):623–623. doi: 10.1093/infdis/142.4.623. [DOI] [PubMed] [Google Scholar]
  110. Larson H. E., Borriello S. P. Infectious diarrhea due to Clostridium perfringens. J Infect Dis. 1988 Feb;157(2):390–391. doi: 10.1093/infdis/157.2.390. [DOI] [PubMed] [Google Scholar]
  111. Larson H. E., Parry J. V., Price A. B., Davies D. R., Dolby J., Tyrrell D. A. Undescribed toxin in pseudomembranous colitis. Br Med J. 1977 May 14;1(6071):1246–1248. doi: 10.1136/bmj.1.6071.1246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Larson H. E., Price A. B., Honour P., Borriello S. P. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet. 1978 May 20;1(8073):1063–1066. doi: 10.1016/s0140-6736(78)90912-1. [DOI] [PubMed] [Google Scholar]
  113. Laverdière M., Robert A., Chicoine R., Salet D., Rosenfeld R. Clostridia in necrotising enterocolitis. Lancet. 1978 Aug 12;2(8085):377–377. doi: 10.1016/s0140-6736(78)92979-3. [DOI] [PubMed] [Google Scholar]
  114. Lawrence G., Cooke R. Experimental pigbel: the production and pathology of necrotizing enteritis due to Clostridium welchii type C in the guinea-pig. Br J Exp Pathol. 1980 Jun;61(3):261–271. [PMC free article] [PubMed] [Google Scholar]
  115. Lee W. H., Riemann H. Correlation of toxic and non-toxic strains of Clostridium botulinum by DNA composition and homology. J Gen Microbiol. 1970 Jan;60(1):117–123. doi: 10.1099/00221287-60-1-117. [DOI] [PubMed] [Google Scholar]
  116. Lee W. H., Riemann H. The genetic relatedness of proteolytic Clostridium botulinum strains. J Gen Microbiol. 1970 Nov;64(1):85–90. doi: 10.1099/00221287-64-1-85. [DOI] [PubMed] [Google Scholar]
  117. Libby J. M., Wilkins T. D. Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun. 1982 Jan;35(1):374–376. doi: 10.1128/iai.35.1.374-376.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Lima A. A., Lyerly D. M., Wilkins T. D., Innes D. J., Guerrant R. L. Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun. 1988 Mar;56(3):582–588. doi: 10.1128/iai.56.3.582-588.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Lindsay D. Clostridium perfringens und Gasbrand. Zentralbl Chir. 1986;111(6):314–323. [PubMed] [Google Scholar]
  120. Long S. S., Gajewski J. L., Brown L. W., Gilligan P. H. Clinical, laboratory, and environmental features of infant botulism in Southeastern Pennsylvania. Pediatrics. 1985 May;75(5):935–941. [PubMed] [Google Scholar]
  121. Ludlow C. L., Naunton R. F., Sedory S. E., Schulz G. M., Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology. 1988 Aug;38(8):1220–1225. doi: 10.1212/wnl.38.8.1220. [DOI] [PubMed] [Google Scholar]
  122. Lyerly D. M., Krivan H. C., Wilkins T. D. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988 Jan;1(1):1–18. doi: 10.1128/cmr.1.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. MACFARLANE M. G. Clostridium oedematiens n-antigen, an enzyme decomposing tropomyosin. Biochem J. 1955 Oct;61(2):308–315. doi: 10.1042/bj0610308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. MACFARLANE M. G. The biochemistry of bacterial toxins; the lecithinase activity of Clostridium haemolyticum toxin. Biochem J. 1950 Sep;47(3):267–270. doi: 10.1042/bj0470267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. MACLENNAN J. D. The histotoxic clostridial infections of man. Bacteriol Rev. 1962 Jun;26:177–276. [PMC free article] [PubMed] [Google Scholar]
  126. MOLLER V., SCHEIBEL I. Preliminary report on the isolation of an apparently new type of CI. botulinum. Acta Pathol Microbiol Scand. 1960;48:80–80. doi: 10.1111/j.1699-0463.1960.tb04741.x. [DOI] [PubMed] [Google Scholar]
  127. MOUSSA R. S. Antigenic formulae for Clostridium septicum and Clostridium chauvoei. J Pathol Bacteriol. 1959 Apr;77(2):341–350. doi: 10.1002/path.1700770204. [DOI] [PubMed] [Google Scholar]
  128. MOUSSA R. S. Complexity of toxins from Clostridium septicum and Clostridium chauvoei. J Bacteriol. 1958 Nov;76(5):538–545. doi: 10.1128/jb.76.5.538-545.1958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. MacDonald K. L., Rutherford G. W., Friedman S. M., Dietz J. R., Kaye B. R., McKinley G. F., Tenney J. H., Cohen M. L. Botulism and botulism-like illness in chronic drug abusers. Ann Intern Med. 1985 May;102(5):616–618. doi: 10.7326/0003-4819-102-5-616. [DOI] [PubMed] [Google Scholar]
  130. MacFARLANE M. G. The biochemistry of bacterial toxins; the identification and immunological relations of lecithinases present in Clostridium oedematiens and Clostridium sordellii toxins. Biochem J. 1948;42(4):590–595. [PubMed] [Google Scholar]
  131. Macheak M. E., Claus K. D., Maloy S. E. Potency testing Clostridium chauvoei-containing bacterins: relationship of agglutination titers and potency tests in cattle. Am J Vet Res. 1972 May;33(5):1053–1058. [PubMed] [Google Scholar]
  132. Martinez R. D., Wilkins T. D. Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun. 1988 May;56(5):1215–1221. doi: 10.1128/iai.56.5.1215-1221.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Matsuoka I., Syoto B., Kurihara K., Kubo S., Syuto B. ADP-ribosylation of specific membrane proteins in pheochromocytoma and primary-cultured brain cells by botulinum neurotoxins type C and D. FEBS Lett. 1987 Jun 1;216(2):295–299. doi: 10.1016/0014-5793(87)80709-3. [DOI] [PubMed] [Google Scholar]
  134. McClane B. A., Hanna P. C., Wnek A. P. Clostridium perfringens enterotoxin. Microb Pathog. 1988 May;4(5):317–323. doi: 10.1016/0882-4010(88)90059-9. [DOI] [PubMed] [Google Scholar]
  135. McClane B. A., Wnek A. P., Hulkower K. I., Hanna P. C. Divalent cation involvement in the action of Clostridium perfringens type A enterotoxin. Early events in enterotoxin action are divalent cation-independent. J Biol Chem. 1988 Feb 15;263(5):2423–2435. [PubMed] [Google Scholar]
  136. McClung L. S. Human Food Poisoning Due to Growth of Clostridium perfringens (C. welchii) in Freshly Cooked Chicken: Preliminary Note. J Bacteriol. 1945 Aug;50(2):229–231. [PMC free article] [PubMed] [Google Scholar]
  137. McClung L. S., Toabe R. The Egg Yolk Plate Reaction for the Presumptive Diagnosis of Clostridium sporogenes and Certain Species of the Gangrene and Botulinum Groups. J Bacteriol. 1947 Feb;53(2):139–147. doi: 10.1128/jb.53.2.139-147.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. McCroskey L. M., Hatheway C. L., Fenicia L., Pasolini B., Aureli P. Characterization of an organism that produces type E botulinal toxin but which resembles Clostridium butyricum from the feces of an infant with type E botulism. J Clin Microbiol. 1986 Jan;23(1):201–202. doi: 10.1128/jcm.23.1.201-202.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. McCroskey L. M., Hatheway C. L. Laboratory findings in four cases of adult botulism suggest colonization of the intestinal tract. J Clin Microbiol. 1988 May;26(5):1052–1054. doi: 10.1128/jcm.26.5.1052-1054.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. McDonel J. L. Clostridium perfringens toxins (type A, B, C, D, E). Pharmacol Ther. 1980;10(3):617–655. doi: 10.1016/0163-7258(80)90031-5. [DOI] [PubMed] [Google Scholar]
  141. McGregor J. A., Soper D. E., Lovell G., Todd J. K. Maternal deaths associated with Clostridium sordellii infection. Am J Obstet Gynecol. 1989 Oct;161(4):987–995. doi: 10.1016/0002-9378(89)90768-0. [DOI] [PubMed] [Google Scholar]
  142. Mellanby J., Green J. How does tetanus toxin act? Neuroscience. 1981;6(3):281–300. doi: 10.1016/0306-4522(81)90123-8. [DOI] [PubMed] [Google Scholar]
  143. Midura T. F., Arnon S. S. Infant botulism. Identification of Clostridium botulinum and its toxins in faeces. Lancet. 1976 Oct 30;2(7992):934–936. doi: 10.1016/s0140-6736(76)90894-1. [DOI] [PubMed] [Google Scholar]
  144. Mitsui N., Mitsui K., Hase J. Purification and some properties of tetanolysin. Microbiol Immunol. 1980;24(7):575–584. doi: 10.1111/j.1348-0421.1980.tb02860.x. [DOI] [PubMed] [Google Scholar]
  145. Mookhtiar K. A., Steinbrink D. R., Van Wart H. E. Mode of hydrolysis of collagen-like peptides by class I and class II Clostridium histolyticum collagenases: evidence for both endopeptidase and tripeptidylcarboxypeptidase activities. Biochemistry. 1985 Nov 5;24(23):6527–6533. doi: 10.1021/bi00344a033. [DOI] [PubMed] [Google Scholar]
  146. Muldrow L. L., Ibeanu G. C., Lee N. I., Bose N. K., Johnson J. Molecular cloning of Clostridium difficile toxin A gene fragment in lambda gt11. FEBS Lett. 1987 Mar 23;213(2):249–253. doi: 10.1016/0014-5793(87)81500-4. [DOI] [PubMed] [Google Scholar]
  147. Murrell T. G., Egerton J. R., Rampling A., Samels J., Walker P. D. The ecology and epidemiology of the pig-bel syndrome in man in New Guinea. J Hyg (Lond) 1966 Sep;64(3):375–396. doi: 10.1017/s0022172400040663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Nakamura S., Kimura I., Yamakawa K., Nishida S. Taxonomic relationships among Clostridium novyi Types A and B, Clostridium haemolyticum and Clostridium botulinum type C. J Gen Microbiol. 1983 May;129(5):1473–1479. doi: 10.1099/00221287-129-5-1473. [DOI] [PubMed] [Google Scholar]
  149. Nakamura S., Okado I., Nakashio S., Nishida S. Clostridium sporogenes isolates and their relationship to C. botulinum based on deoxyribonucleic acid reassociation. J Gen Microbiol. 1977 Jun;100(2):395–401. doi: 10.1099/00221287-100-2-395. [DOI] [PubMed] [Google Scholar]
  150. Nakamura S., Tanabe N., Yamakawa K., Nishida S. Cytotoxin production by Clostridium sordellii strains. Microbiol Immunol. 1983;27(6):495–502. doi: 10.1111/j.1348-0421.1983.tb00611.x. [DOI] [PubMed] [Google Scholar]
  151. Naylor R. D., Martin P. K., Sharpe R. T. Detection of Clostridium perfringens epsilon toxin by ELISA. Res Vet Sci. 1987 Mar;42(2):255–256. [PubMed] [Google Scholar]
  152. Nees S., Veh R. W., Schauer R. Purification and characterization of neuraminidase from Clostridium perfringens. Hoppe Seylers Z Physiol Chem. 1975 Jun;356(6):1027–1042. doi: 10.1515/bchm2.1975.356.s1.1027. [DOI] [PubMed] [Google Scholar]
  153. Niilo L. Clostridium perfringens in animal disease: a review of current knowledge. Can Vet J. 1980 May;21(5):141–148. [PMC free article] [PubMed] [Google Scholar]
  154. Nishida S., Imaizumi M. Toxigenicity of Clostridium histolyticum. J Bacteriol. 1966 Feb;91(2):477–483. doi: 10.1128/jb.91.2.477-483.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Notermans S., Hagenaars A. M., Kozaki S. The enzyme-linked immunosorbent assay (ELISA) for the detection and determination of Clostridium botulinum toxins A, B, and E. Methods Enzymol. 1982;84:223–238. doi: 10.1016/0076-6879(82)84020-2. [DOI] [PubMed] [Google Scholar]
  156. Nukina M., Mochida Y., Sakaguchi S., Sakaguchi G. Purification of Clostridium botulinum type G progenitor toxin. Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Apr;268(2):220–227. doi: 10.1016/s0176-6724(88)80006-3. [DOI] [PubMed] [Google Scholar]
  157. OAKLEY C. L. Bacterial toxins and classification. J Gen Microbiol. 1955 Apr;12(2):344–347. doi: 10.1099/00221287-12-2-344. [DOI] [PubMed] [Google Scholar]
  158. OAKLEY C. L., WARRACK G. H. Routine typing of Clostridium welchii. J Hyg (Lond) 1953 Mar;51(1):102–107. doi: 10.1017/s0022172400015527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. OAKLEY C. L., WARRACK G. H. The ACRA test as a means of estimating hyaluronidase, deoxyribonuclease and their antibodies. J Pathol Bacteriol. 1951 Jan;63(1):45–55. doi: 10.1002/path.1700630106. [DOI] [PubMed] [Google Scholar]
  160. OAKLEY C. L., WARRACK G. H. The alpha, beta and gamma antigens of Clostridium histolyticum (Weinberg & Séguin, 1916). J Gen Microbiol. 1950 Sep;4(3):365–373. doi: 10.1099/00221287-4-3-365. [DOI] [PubMed] [Google Scholar]
  161. OAKLEY C. L., WARRACK G. H. The soluble antigens of Clostridium oedematiens type D (CI. haemolyticum). J Pathol Bacteriol. 1959 Oct;78:543–551. doi: 10.1002/path.1700780221. [DOI] [PubMed] [Google Scholar]
  162. Ohashi Y., Kamiya T., Fujiwara M., Narumiya S. ADP-ribosylation by type C1 and D botulinum neurotoxins: stimulation by guanine nucleotides and inhibition by guanidino-containing compounds. Biochem Biophys Res Commun. 1987 Feb 13;142(3):1032–1038. doi: 10.1016/0006-291x(87)91518-x. [DOI] [PubMed] [Google Scholar]
  163. Ohashi Y., Narumiya S. ADP-ribosylation of a Mr 21,000 membrane protein by type D botulinum toxin. J Biol Chem. 1987 Feb 5;262(4):1430–1433. [PubMed] [Google Scholar]
  164. Ohishi I., Iwasaki M., Sakaguchi G. Purification and characterization of two components of botulinum C2 toxin. Infect Immun. 1980 Dec;30(3):668–673. doi: 10.1128/iai.30.3.668-673.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Ohishi I., Iwasaki M., Sakaguchi G. Vascular permeability activity of botulinum C2 toxin elicited by cooperation of two dissimilar protein components. Infect Immun. 1981 Mar;31(3):890–895. doi: 10.1128/iai.31.3.890-895.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  166. Ohishi I. Response of mouse intestinal loop to botulinum C2 toxin: enterotoxic activity induced by cooperation of nonlinked protein components. Infect Immun. 1983 May;40(2):691–695. doi: 10.1128/iai.40.2.691-695.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Ohishi I., Sugii S., Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun. 1977 Apr;16(1):107–109. doi: 10.1128/iai.16.1.107-109.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Ohishi I., Tsuyama S. ADP-ribosylation of nonmuscle actin with component I of C2 toxin. Biochem Biophys Res Commun. 1986 Apr 29;136(2):802–806. doi: 10.1016/0006-291x(86)90511-5. [DOI] [PubMed] [Google Scholar]
  169. Okabe A., Shimizu T., Hayashi H. Cloning and sequencing of a phospholipase C gene of Clostridium perfringens. Biochem Biophys Res Commun. 1989 Apr 14;160(1):33–39. doi: 10.1016/0006-291x(89)91616-1. [DOI] [PubMed] [Google Scholar]
  170. Ottlinger M. E., Lin S. Clostridium difficile toxin B induces reorganization of actin, vinculin, and talin in cultured cells. Exp Cell Res. 1988 Jan;174(1):215–229. doi: 10.1016/0014-4827(88)90156-5. [DOI] [PubMed] [Google Scholar]
  171. Patton N. M., Holmes H. T., Riggs R. J., Cheeke P. R. Enterotoxemia in rabbits. Lab Anim Sci. 1978 Oct;28(5):536–540. [PubMed] [Google Scholar]
  172. Pelfrey T. M., Turk R. P., Peoples J. B., Elliott D. W. Surgical aspects of Clostridium septicum septicemia. Arch Surg. 1984 May;119(5):546–550. doi: 10.1001/archsurg.1984.01390170044009. [DOI] [PubMed] [Google Scholar]
  173. Phillips A. W., Batty I., Wood R. D. A partial characterization of the alpha-toxin of Clostridium oedematiens type B. Eur J Biochem. 1970 Jun;14(2):367–371. doi: 10.1111/j.1432-1033.1970.tb00298.x. [DOI] [PubMed] [Google Scholar]
  174. Pickett J., Berg B., Chaplin E., Brunstetter-Shafer M. A. Syndrome of botulism in infancy: clinical and electrophysiologic study. N Engl J Med. 1976 Sep 30;295(14):770–772. doi: 10.1056/NEJM197609302951407. [DOI] [PubMed] [Google Scholar]
  175. Popoff M. R., Boquet P. Clostridium spiroforme toxin is a binary toxin which ADP-ribosylates cellular actin. Biochem Biophys Res Commun. 1988 May 16;152(3):1361–1368. doi: 10.1016/s0006-291x(88)80435-2. [DOI] [PubMed] [Google Scholar]
  176. Popoff M. R., Dodin A. Survey of neuraminidase production by Clostridium butyricum, Clostridium beijerinckii, and Clostridium difficile strains from clinical and nonclinical sources. J Clin Microbiol. 1985 Nov;22(5):873–876. doi: 10.1128/jcm.22.5.873-876.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  177. Popoff M. R. Purification and characterization of Clostridium sordellii lethal toxin and cross-reactivity with Clostridium difficile cytotoxin. Infect Immun. 1987 Jan;55(1):35–43. doi: 10.1128/iai.55.1.35-43.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  178. Popoff M. R., Rubin E. J., Gill D. M., Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun. 1988 Sep;56(9):2299–2306. doi: 10.1128/iai.56.9.2299-2306.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Pothoulakis C., Barone L. M., Ely R., Faris B., Clark M. E., Franzblau C., LaMont J. T. Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem. 1986 Jan 25;261(3):1316–1321. [PubMed] [Google Scholar]
  180. Prescott L. M., Altenbern R. A. Detection of bacteriophages from two strains of Clostridium tetani. J Virol. 1967 Oct;1(5):1085–1086. doi: 10.1128/jvi.1.5.1085-1086.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Prescott L. M., Altenbern R. A. Inducible lysis clostridium tetani. J Bacteriol. 1967 Apr;93(4):1220–1226. doi: 10.1128/jb.93.4.1220-1226.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  182. Princewill T. J., Oakley C. L. Deoxyribonucleases and hyaluronidases of Clostridium septicum and Clostridium chauvoei. III. Relationship between the two organisms. Med Lab Sci. 1976 Apr;33(2):10–118. [PubMed] [Google Scholar]
  183. ROSS H. E., WARREN M. E., BARNES J. M. Clostridium welchii iota toxin; its activation by trypsin. J Gen Microbiol. 1949 Jan;3(1):148–152. doi: 10.1099/00221287-3-1-148. [DOI] [PubMed] [Google Scholar]
  184. Richardson M., Granum P. E. Sequence of the amino-terminal part of enterotoxin from Clostridium perfringens type A: identification of points of trypsin activation. Infect Immun. 1983 Jun;40(3):943–949. doi: 10.1128/iai.40.3.943-949.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  185. Richardson M., Granum P. E. The amino acid sequence of the enterotoxin from Clostridium perfringens type A. FEBS Lett. 1985 Mar 25;182(2):479–484. doi: 10.1016/0014-5793(85)80358-6. [DOI] [PubMed] [Google Scholar]
  186. Rifkin G. D., Fekety F. R., Silva J., Jr Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet. 1977 Nov 26;2(8048):1103–1106. doi: 10.1016/s0140-6736(77)90547-5. [DOI] [PubMed] [Google Scholar]
  187. Roggentin P., Rothe B., Lottspeich F., Schauer R. Cloning and sequencing of a Clostridium perfringens sialidase gene. FEBS Lett. 1988 Sep 26;238(1):31–34. doi: 10.1016/0014-5793(88)80219-9. [DOI] [PubMed] [Google Scholar]
  188. Rood J. I., Wilkinson R. G. Relationship between hemagglutinin and sialidase from Clostridium perfringens CN3870: chromatographic characterization of the biologically active proteins. J Bacteriol. 1976 May;126(2):831–844. doi: 10.1128/jb.126.2.831-844.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Rothman S. W., Brown J. E., Diecidue A., Foret D. A. Differential cytotoxic effects of toxins A and B isolated from Clostridium difficile. Infect Immun. 1984 Nov;46(2):324–331. doi: 10.1128/iai.46.2.324-331.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Rothman S. W., Gentry M. K., Brown J. E., Foret D. A., Stone M. J., Strickler M. P. Immunochemical and structural similarities in toxin A and toxin B of Clostridium difficile shown by binding to monoclonal antibodies. Toxicon. 1988;26(6):583–597. doi: 10.1016/0041-0101(88)90239-5. [DOI] [PubMed] [Google Scholar]
  191. Rubin E. J., Gill D. M., Boquet P., Popoff M. R. Functional modification of a 21-kilodalton G protein when ADP-ribosylated by exoenzyme C3 of Clostridium botulinum. Mol Cell Biol. 1988 Jan;8(1):418–426. doi: 10.1128/mcb.8.1.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  192. Rutter J. M., Collee J. G. Studies on the soluble antigens of Clostridium oedematiens (Cl. novyi). J Med Microbiol. 1969 Nov 4;2(4):395–417. doi: 10.1099/00222615-2-4-395. [DOI] [PubMed] [Google Scholar]
  193. Rösener S., Chhatwal G. S., Aktories K. Botulinum ADP-ribosyltransferase C3 but not botulinum neurotoxins C1 and D ADP-ribosylates low molecular mass GTP-binding proteins. FEBS Lett. 1987 Nov 16;224(1):38–42. doi: 10.1016/0014-5793(87)80418-0. [DOI] [PubMed] [Google Scholar]
  194. STERNE M., WARRACK G. H. THE TYPES OF CLOSTRIDIUM PERFRINGENS. J Pathol Bacteriol. 1964 Jul;88:279–283. [PubMed] [Google Scholar]
  195. STERNE M., WARRACK G. H. The interactions between Clostridium septicum and Clostridium histolyticum toxins and antitoxins. J Pathol Bacteriol. 1962 Oct;84:277–288. doi: 10.1002/path.1700840202. [DOI] [PubMed] [Google Scholar]
  196. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther. 1982;19(2):165–194. doi: 10.1016/0163-7258(82)90061-4. [DOI] [PubMed] [Google Scholar]
  197. Sakaguchi G., Uemura T., Riemann H. P. Simplified method for purification of Clostridium perfringens type A enterotoxin. Appl Microbiol. 1973 Nov;26(5):762–767. doi: 10.1128/am.26.5.762-767.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  198. Sakurai J., Fujii Y., Dezaki K., Endo K. Effect of Clostridium perfringens beta toxin on blood pressure of rats. Microbiol Immunol. 1984;28(1):23–31. doi: 10.1111/j.1348-0421.1984.tb02944.x. [DOI] [PubMed] [Google Scholar]
  199. Sakurai J., Fujii Y., Matsuura M., Endo K. Pharmacological effect of beta toxin of Clostridium perfringens type C on rats. Microbiol Immunol. 1981;25(5):423–432. doi: 10.1111/j.1348-0421.1981.tb00045.x. [DOI] [PubMed] [Google Scholar]
  200. Sakurai J., Fujii Y. Purification and characterization of Clostridium perfringens beta toxin. Toxicon. 1987;25(12):1301–1310. doi: 10.1016/0041-0101(87)90008-0. [DOI] [PubMed] [Google Scholar]
  201. Sathyamoorthy V., DasGupta B. R. Partial amino acid sequences of the heavy and light chains of botulinum neurotoxin type E. Biochem Biophys Res Commun. 1985 Mar 29;127(3):768–772. doi: 10.1016/s0006-291x(85)80009-7. [DOI] [PubMed] [Google Scholar]
  202. Sathyamoorthy V., DasGupta B. R. Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E. J Biol Chem. 1985 Sep 5;260(19):10461–10466. [PubMed] [Google Scholar]
  203. Schering B., Bärmann M., Chhatwal G. S., Geipel U., Aktories K. ADP-ribosylation of skeletal muscle and non-muscle actin by Clostridium perfringens iota toxin. Eur J Biochem. 1988 Jan 15;171(1-2):225–229. doi: 10.1111/j.1432-1033.1988.tb13780.x. [DOI] [PubMed] [Google Scholar]
  204. Schmidt J. J., Sathyamoorthy V., DasGupta B. R. Partial amino acid sequence of the heavy and light chains of botulinum neurotoxin type A. Biochem Biophys Res Commun. 1984 Mar 30;119(3):900–904. doi: 10.1016/0006-291x(84)90858-1. [DOI] [PubMed] [Google Scholar]
  205. Schmidt J. J., Sathyamoorthy V., DasGupta B. R. Partial amino acid sequences of botulinum neurotoxins types B and E. Arch Biochem Biophys. 1985 May 1;238(2):544–548. doi: 10.1016/0003-9861(85)90198-5. [DOI] [PubMed] [Google Scholar]
  206. Shone C. C., Hambleton P., Melling J. Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur J Biochem. 1985 Aug 15;151(1):75–82. doi: 10.1111/j.1432-1033.1985.tb09070.x. [DOI] [PubMed] [Google Scholar]
  207. Siegel L. S., Johnson-Winegar A. D., Sellin L. C. Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F. Toxicol Appl Pharmacol. 1986 Jun 30;84(2):255–263. doi: 10.1016/0041-008x(86)90133-x. [DOI] [PubMed] [Google Scholar]
  208. Simpson L. L. A comparison of the pharmacological properties of Clostridium botulinum type C1 and C2 toxins. J Pharmacol Exp Ther. 1982 Dec;223(3):695–701. [PubMed] [Google Scholar]
  209. Simpson L. L. Molecular basis for the pharmacological actions of Clostridium botulinum type C2 toxin. J Pharmacol Exp Ther. 1984 Sep;230(3):665–669. [PubMed] [Google Scholar]
  210. Simpson L. L. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol. 1986;26:427–453. doi: 10.1146/annurev.pa.26.040186.002235. [DOI] [PubMed] [Google Scholar]
  211. Simpson L. L., Stiles B. G., Zepeda H. H., Wilkins T. D. Molecular basis for the pathological actions of Clostridium perfringens iota toxin. Infect Immun. 1987 Jan;55(1):118–122. doi: 10.1128/iai.55.1.118-122.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  212. Simpson L. L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981 Sep;33(3):155–188. [PubMed] [Google Scholar]
  213. Smith L. D. The occurrence of Clostridium botulinum and Clostridium tetani in the soil of the United States. Health Lab Sci. 1978 Apr;15(2):74–80. [PubMed] [Google Scholar]
  214. Smith L. D. Virulence factors of Clostridium perfringens. Rev Infect Dis. 1979 Mar-Apr;1(2):254–262. doi: 10.1093/clinids/1.2.254. [DOI] [PubMed] [Google Scholar]
  215. Sonnabend O. A., Sonnabend W. F., Krech U., Molz G., Sigrist T. Continuous microbiological and pathological study of 70 sudden and unexpected infant deaths: toxigenic intestinal clostridium botulinum infection in 9 cases of sudden infant death syndrome. Lancet. 1985 Feb 2;1(8423):237–241. doi: 10.1016/s0140-6736(85)91025-6. [DOI] [PubMed] [Google Scholar]
  216. Sonnabend W. F., Sonnabend U. P., Krech T. Isolation of Clostridium botulinum type G from Swiss soil specimens by using sequential steps in an identification scheme. Appl Environ Microbiol. 1987 Aug;53(8):1880–1884. doi: 10.1128/aem.53.8.1880-1884.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  217. Stark P. L., Lee A. Clostridia isolated from the feces of infants during the first year of life. J Pediatr. 1982 Mar;100(3):362–365. doi: 10.1016/s0022-3476(82)80430-7. [DOI] [PubMed] [Google Scholar]
  218. Stark R. L., Duncan C. L. Purification and biochemical properties of Clostridium perfringens type A enterotoxin. Infect Immun. 1972 Nov;6(5):662–673. doi: 10.1128/iai.6.5.662-673.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  219. Stevens D. L., Troyer B. E., Merrick D. T., Mitten J. E., Olson R. D. Lethal effects and cardiovascular effects of purified alpha- and theta-toxins from Clostridium perfringens. J Infect Dis. 1988 Feb;157(2):272–279. doi: 10.1093/infdis/157.2.272. [DOI] [PubMed] [Google Scholar]
  220. Stiles B. G., Wilkins T. D. Clostridium perfringens iota toxin: synergism between two proteins. Toxicon. 1986;24(8):767–773. doi: 10.1016/0041-0101(86)90101-7. [DOI] [PubMed] [Google Scholar]
  221. Stiles B. G., Wilkins T. D. Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect Immun. 1986 Dec;54(3):683–688. doi: 10.1128/iai.54.3.683-688.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  222. Strom M. S., Eklund M. W., Poysky F. T. Plasmids in Clostridium botulinum and related Clostridium species. Appl Environ Microbiol. 1984 Nov;48(5):956–963. doi: 10.1128/aem.48.5.956-963.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  223. Suen J. C., Hatheway C. L., Steigerwalt A. G., Brenner D. J. Genetic confirmation of identities of neurotoxigenic Clostridium baratii and Clostridium butyricum implicated as agents of infant botulism. J Clin Microbiol. 1988 Oct;26(10):2191–2192. doi: 10.1128/jcm.26.10.2191-2192.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  224. Sugahara T., Takahashi T., Yamaya S., Ohsaka A. Vascular permeability increase by alpha-toxin (phospholipase C) of Clostridium perfringens. Toxicon. 1977;15(1):81–87. doi: 10.1016/0041-0101(77)90074-5. [DOI] [PubMed] [Google Scholar]
  225. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev. 1980 Sep;44(3):419–448. doi: 10.1128/mr.44.3.419-448.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  226. Sullivan N. M., Pellett S., Wilkins T. D. Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun. 1982 Mar;35(3):1032–1040. doi: 10.1128/iai.35.3.1032-1040.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  227. Sutton R. G., Hobbs B. C. Food poisoning caused by heat-sensitive Clostridium welchii. A report of five recent outbreaks. J Hyg (Lond) 1968 Mar;66(1):135–146. doi: 10.1017/s0022172400041000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  228. Swiatek P. J., Allen S. D., Siders J. A., Lee C. H. DNase production by Clostridium septicum. J Clin Microbiol. 1987 Feb;25(2):437–438. doi: 10.1128/jcm.25.2.437-438.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  229. Taguchi R., Ikezawa H. Phospholipase C from Clostridium novyi type A. I. Biochim Biophys Acta. 1975 Oct 21;409(1):75–85. doi: 10.1016/0005-2760(75)90082-x. [DOI] [PubMed] [Google Scholar]
  230. Takahashi S., Seifter S., Binder M. Elastolytic activities of Clostridium histolyticum. Biochem Biophys Res Commun. 1970;39(6):1058–1064. doi: 10.1016/0006-291x(70)90666-2. [DOI] [PubMed] [Google Scholar]
  231. Taylor N. S., Thorne G. M., Bartlett J. G. Comparison of two toxins produced by Clostridium difficile. Infect Immun. 1981 Dec;34(3):1036–1043. doi: 10.1128/iai.34.3.1036-1043.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  232. Tenbroeck C., Bauer J. H. THE TETANUS BACILLUS AS AN INTESTINAL SAPROPHYTE IN MAN. J Exp Med. 1922 Aug 31;36(3):261–271. doi: 10.1084/jem.36.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  233. Titball R. W., Hunter S. E., Martin K. L., Morris B. C., Shuttleworth A. D., Rubidge T., Anderson D. W., Kelly D. C. Molecular cloning and nucleotide sequence of the alpha-toxin (phospholipase C) of Clostridium perfringens. Infect Immun. 1989 Feb;57(2):367–376. doi: 10.1128/iai.57.2.367-376.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  234. Tixier G., Alouf J. E. Essai de purification et propriétés de la toxine delta de Clostridium perfringens type C. Ann Microbiol (Paris) 1976 Nov-Dec;127B(4):509–524. [PubMed] [Google Scholar]
  235. Triadafilopoulos G., Pothoulakis C., O'Brien M. J., LaMont J. T. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology. 1987 Aug;93(2):273–279. doi: 10.1016/0016-5085(87)91014-6. [DOI] [PubMed] [Google Scholar]
  236. Tsai S. C., Adamik R., Moss J., Aktories K. Separation of the 24 kDa substrate for botulinum C3 ADP-ribosyltransferase and the cholera toxin ADP-ribosylation factor. Biochem Biophys Res Commun. 1988 May 16;152(3):957–961. doi: 10.1016/s0006-291x(88)80376-0. [DOI] [PubMed] [Google Scholar]
  237. Tso J. Y., Siebel C. Cloning and expression of the phospholipase C gene from Clostridium perfringens and Clostridium bifermentans. Infect Immun. 1989 Feb;57(2):468–476. doi: 10.1128/iai.57.2.468-476.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  238. Tsui J. K., Fross R. D., Calne S., Calne D. B. Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci. 1987 Aug;14(3 Suppl):533–535. doi: 10.1017/s0317167100038063. [DOI] [PubMed] [Google Scholar]
  239. Tweten R. K. Cloning and expression in Escherichia coli of the perfringolysin O (theta-toxin) gene from Clostridium perfringens and characterization of the gene product. Infect Immun. 1988 Dec;56(12):3228–3234. doi: 10.1128/iai.56.12.3228-3234.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  240. Tweten R. K. Nucleotide sequence of the gene for perfringolysin O (theta-toxin) from Clostridium perfringens: significant homology with the genes for streptolysin O and pneumolysin. Infect Immun. 1988 Dec;56(12):3235–3240. doi: 10.1128/iai.56.12.3235-3240.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  241. Van Wart H. E., Steinbrink D. R. Complementary substrate specificities of class I and class II collagenases from Clostridium histolyticum. Biochemistry. 1985 Nov 5;24(23):6520–6526. doi: 10.1021/bi00344a032. [DOI] [PubMed] [Google Scholar]
  242. Vandekerckhove J., Schering B., Bärmann M., Aktories K. Clostridium perfringens iota toxin ADP-ribosylates skeletal muscle actin in Arg-177. FEBS Lett. 1987 Dec 10;225(1-2):48–52. doi: 10.1016/0014-5793(87)81129-8. [DOI] [PubMed] [Google Scholar]
  243. Vargaftig B. B., Lefort J., Giroux E. L. Haemorrhagic and inflammatory properties of collagenase from C. histolyticum. Agents Actions. 1976 Sep;6(5):627–635. doi: 10.1007/BF01971582. [DOI] [PubMed] [Google Scholar]
  244. Weickert M. J., Chambliss G. H., Sugiyama H. Production of toxin by Clostridium botulinum type A strains cured by plasmids. Appl Environ Microbiol. 1986 Jan;51(1):52–56. doi: 10.1128/aem.51.1.52-56.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  245. Williams-Walls N. J. Clostridium botulinum Type F: Isolation from Crabs. Science. 1968 Oct 18;162(3851):375–376. doi: 10.1126/science.162.3851.375. [DOI] [PubMed] [Google Scholar]
  246. Wnek A. P., McClane B. A. Identification of a 50,000 Mr protein from rabbit brush border membranes that binds Clostridium perfringens enterotoxin. Biochem Biophys Res Commun. 1983 May 16;112(3):1099–1105. doi: 10.1016/0006-291x(83)91731-x. [DOI] [PubMed] [Google Scholar]
  247. Wren B. W., Clayton C. L., Mullany P. P., Tabaqchali S. Molecular cloning and expression of Clostridium difficile toxin A in Escherichia coli K12. FEBS Lett. 1987 Dec 10;225(1-2):82–86. doi: 10.1016/0014-5793(87)81135-3. [DOI] [PubMed] [Google Scholar]
  248. Wu J. I., Riemann H., Lee W. H. Thermal stability of the deoxyribonucleic acid hybrids between the proteolytic strains of Clostridium botulinum and Clostridium sporogenes. Can J Microbiol. 1972 Jan;18(1):97–99. doi: 10.1139/m72-016. [DOI] [PubMed] [Google Scholar]
  249. Yamakawa K., Nakamura S., Nishida S. Separation of two cytotoxins of Clostridium sordellii strains. Microbiol Immunol. 1985;29(6):553–557. doi: 10.1111/j.1348-0421.1985.tb00857.x. [DOI] [PubMed] [Google Scholar]
  250. Yamakawa K., Tanabe N., Okada Y., Nishida S., Nakamura S. Rabbit ileal loop responses to Clostridium sordellii strains. Microbiol Immunol. 1983;27(9):807–809. doi: 10.1111/j.1348-0421.1983.tb00646.x. [DOI] [PubMed] [Google Scholar]
  251. Yamakawa Y., Ito A., Sato H. Theta-toxin of Clostridium perfringens. I. Purification and some properties. Biochim Biophys Acta. 1977 Oct 26;494(2):301–313. doi: 10.1016/0005-2795(77)90159-3. [DOI] [PubMed] [Google Scholar]
  252. Yoshida E., Noda H. Isolation and characterization of collagenases I and II from Clostridium histolyticum. Biochim Biophys Acta. 1965 Sep 20;105(3):562–574. doi: 10.1016/s0926-6593(65)80239-9. [DOI] [PubMed] [Google Scholar]
  253. ZEISSLER J., RASSFELD-STERNBERG L. Enteritis necroticans due to Clostridium welchii type F. Br Med J. 1949 Feb 12;1(4597):267–269. doi: 10.1136/bmj.1.4597.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  254. al-Khatib G. Beitrage zur Clostridiendifferenzierung. 6. Zur Differenzierung von Cl. septicum and Cl. chauvoei. Arch Exp Veterinarmed. 1969 Nov;23(5):963–970. [PubMed] [Google Scholar]
  255. al-Khatib G. Beiträge zur Clostridiendifferenzierung. II. Die Letalfaktoren der Toxine pathogener Clostridien, ihre Neutralisation und Bedeutung für die Differenzierung. Arch Exp Veterinarmed. 1968;22(3):659–665. [PubMed] [Google Scholar]
  256. van Heyningen S. Binding of ganglioside by the chains of tetanus toxin. FEBS Lett. 1976 Sep 15;68(1):5–7. doi: 10.1016/0014-5793(76)80391-2. [DOI] [PubMed] [Google Scholar]
  257. von Eichel-Streiber C., Harperath U., Bosse D., Hadding U. Purification of two high molecular weight toxins of Clostridium difficile which are antigenically related. Microb Pathog. 1987 May;2(5):307–318. doi: 10.1016/0882-4010(87)90073-8. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES